


A

()

一、本次非公开发行股票的背景



1

1

| | | |
|---|------|-----|
| | | |
| 1 | | 50% |
| 2 | 2020 | 90% |
| 3 | 2020 | 10% |
| | GMP | 100 |


| | | |
|---|--|--|
| | | |
| 4 | | |

2011 15,126

2015 26,703 15.30%

2020

10%



IMS 2020

2

2015

450

2010

2017 6

ICH

8

2015

2010

GMP

IMS Health

Global

Medicines Use in 2020

2010

2015

2010

8,870

2015

10,688

,

6.2%

IMS Health

2020

14,000-14,300

2016

2020

4%-7%

2010%36b982A4CB0382471DD12A34382499F59F1E1D5833086639291C099M1D4FFD0F3503608F9

3

2016 3 5 CFDA

GMP

2015 7

FDA

4

WHO 2.4

65

1 59

7.18%

1


2,000

2010

20%

2011 68.81 2015 162.76
 22.4% 2020 200
 2015
 80%

2016-2020



2017 5

CFDA


2

1

2030

2030


2016



2016

2017 5


2020 12.9% 2 17% 1990 1986 1990



2

80

90




3

2010 1

| | | |
|---|----------------------|-----------------------|
| 1 | 2013 54 | |
| 2 | 2015-2020 2015 14 | 2015 0.52 2020 1.5 |
| 3 | 2015 38 | 10% |

| | | |
|---|-----------------|-------------|
| 4 | 2015 45 | |
| 5 | 117 2015 | 2020 25% |
| 6 | 2017 2017 50 | |



4

R

RGI

1

2 RGI

PGD

PGD

Dr.Yevy Verlinsky


RGI

RGI

3

JCI

JCI CAP



2015

RGI

RGI

二、本次非公开发行股票的目的

1

FDA

GMP

2

RGI

三、本次发行对象选择范围、数量和标准的适当性

5

2

四、本次发行定价的原则、依据、方法和程序的合理性

A

90%

=

/

2

3

4

20%

18

(二) 确定发行方式的审议和批准程序合法合规

七、本次发行对于即期回报的摊薄及公司拟采取的措施

1

2

3

4

3

[2013]43

2018 -2020

八、结论

2018 3 19